Management and Staging of pT3N0 (Stage IIA) Colon Cancer

Definition and Pathologic Staging

pT3N0 colon cancer corresponds to Stage IIA disease: the tumor penetrates the muscularis propria into the pericolorectal tissues without regional lymph‑node involvement, and the N0 classification is reliable only when ≥ 12 lymph nodes are examined in the surgical specimen【@1】.

The presence of lymphovascular invasion, perineural invasion, or poor histologic differentiation identifies a high‑risk subset of pT3N0 tumors associated with worse survival【@1】.

Contrast‑enhanced CT of the chest, abdomen, and pelvis is the preferred and standard imaging modality for detecting liver, lung, and peritoneal metastases in colon cancer, and should be performed if not already completed pre‑operatively【@1】【@2】【@3】.
Contrast‑enhanced MRI is recommended when CT identifies indeterminate liver lesions or when superior characterization of locally advanced disease is needed【@1】.
Baseline staging CT is essential because identification of distant metastases is the primary determinant of subsequent management decisions【@2】【@3】.

A complete colonoscopy should be performed within 3–6 months after resection if it was not done pre‑operatively, to detect synchronous lesions【@1】.
A baseline carcinoembryonic antigen (CEA) level must be obtained to serve as a reference for future surveillance【@1】.

For pT3N0 disease without high‑risk features, surgery alone may be sufficient.
Patients whose tumors exhibit high‑risk pathologic characteristics (e.g., obstructing lesions, inadequate nodal harvest, lymphovascular invasion, poor differentiation, or extramural spread > 5 mm) should be evaluated for adjuvant chemotherapy【@1】.
Microsatellite instability (MSI) / mismatch‑repair (MMR) testing is mandatory in all Stage II colon cancers; tumors that are dMMR/MSI‑high generally do not benefit from fluoropyrimidine‑based adjuvant chemotherapy【@1】.

Assuming N0 status without confirming adequate lymph‑node harvest can lead to understaging and poorer outcomes.
Neglecting high‑risk pathologic features may miss patients who would benefit from adjuvant therapy.
Omitting baseline staging CT can result in failure to detect distant metastases, which critically influences treatment planning【@2】【@3】.